There are currently 148 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385
Recruiting
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a Dose Expansion: To investigate the safety and tolerability of DS-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: University of California, Los Angeles, Los Angeles, California +17 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627
Recruiting
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer
NCT05790460
Recruiting
The goal of this trial is to design and test a telehealth nurse navigation intervention for patients with suspected locally advanced/metastatic NSCLC to improve timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2023
Locations: Charu Aggarwal, Philadelphia, Pennsylvania
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566
Recruiting
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: OPN Healthcare, Inc., Glendale, California +2 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
NCT04263090
Recruiting
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV
Register for Updates
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT04789486
Recruiting
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835
Recruiting
This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +7 locations
Conditions: Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Ovarian Cancer, Bladder Cancer, Cancer of Unknown Primary Site, Oesophageal Cancer, Prostate Cancer, Biliary Tract Cancer
Register for Updates
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859
Recruiting
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Register for Updates
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
NCT04297605
Recruiting
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: University of Rochester, Rochester, New York +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT04152499
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma Small cell lung can... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2022
Locations: University of California Los Angeles, Los Angeles, California +55 locations
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Redwood City, Redwood City, California
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma
Register for Updates
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
NCT05430009
Recruiting
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Liver Metastases, Non-small Cell Lung Cancer
Register for Updates